Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Apr 23 16:42 ET
Shuttle Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933
Apr 5 17:10 ET
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Fourth Quarter 2023 Corporate Update
Mar 22 09:02 ET
Shuttle Pharmaceuticals | 424B3: Prospectus
Mar 22 06:11 ET
Shuttle Pharmaceuticals | 10-K: Annual report
Mar 21 17:32 ET
Shuttle Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Senanayake Chris
Mar 14 17:06 ET
Shuttle Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Vander Hoek Michael
Mar 8 18:21 ET
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmicals Receives Notice of Nasdaq's Failure to Satisfy Continued Listing Rules and CEO Anatoly Dritschilo to Attend Emerging Growth Conference on March 6, 2024
Mar 5 09:02 ET
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
Feb 13 08:04 ET
Shuttle Pharmaceuticals | 8-K: Asset Purchase Agreement
Feb 5 16:28 ET
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Jan 8 00:00 ET
Shuttle Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Brown Milton
Jan 2 00:00 ET
Shuttle Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Jacobs Bette
Dec 20, 2023 21:51 ET
Shuttle Pharmaceuticals | 8-K: Poll Results of 2023 Stockholders Meeting
Dec 19, 2023 17:10 ET
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
Dec 11, 2023 09:00 ET
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023
Nov 30, 2023 09:00 ET
Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
Nov 14, 2023 09:12 ET
Shuttle Pharmaceuticals: Q3 2023 Earnings Report
Nov 13, 2023 16:21 ET
Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement
Oct 30, 2023 17:14 ET
Shuttle Pharmaceuticals | ARS: Annual Report to Security Holders
Oct 20, 2023 16:15 ET
No Data
No Data